Takeda (TAK) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Takeda is a global biopharmaceutical leader committed to delivering life-transforming treatments, with a strategic focus on rare diseases, oncology, neuroscience, and gastroenterology. Its position was solidified by the landmark $62 billion acquisition of Shire in 2019, which expanded its footprint in rare diseases and plasma-derived therapies. The company employs a modality-agnostic, externalized R&D strategy, leveraging deep internal expertise in biologics and small molecules while aggressively partnering to access cutting-edge science. Takeda's financial foundation is built on a portfolio of marketed products, with a disciplined capital allocation strategy aimed at fueling innovation and sustainable growth.

Rare DiseasesGastroenterologyOncologyNeurosciencePlasma-Derived Therapies

Technology Platform

Modality-agnostic, externalized R&D strategy with deep internal expertise in biologics, small molecules, and a highly differentiated, vertically integrated platform for plasma-derived therapies.

Opportunities

Significant growth potential lies in the launch of late-stage pipeline assets in rare diseases and neuroscience, geographic expansion of its plasma-derived therapy portfolio, and leveraging its external innovation model to access next-generation modalities like cell & gene therapy.

The stable cash flow from its core business provides ample fuel for strategic investment.

Risk Factors

Key risks include clinical trial failures in its pivotal pipeline, impending patent expirations for major products like ENTYVIO, pricing pressures and supply complexities in the plasma business, and the operational challenge of managing innovation across a vast global organization.

Competitive Landscape

Takeda competes with large-cap peers like CSL, Grifols, and Sanofi in plasma and rare diseases, and with J&J and AbbVie in gastroenterology. Its integrated plasma platform and externalized R&D model are key differentiators in this competitive landscape.

More companies in Biologics / Biosimilars →More companies in United States →